New Thinking, New Strategies in Advanced Urothelial Carcinoma

STATEMENT OF NEED

Bladder cancer is the sixth most common malignancy among adults in the United States. Approximately 80,470 new cases are diagnosed annually and 17,670 people die of the disease. More than 90% of patients with bladder cancer have the urothelial carcinoma subtype, which has a high rate of recurrence whether it is low or high grade. Approximately half of all bladder cancers are diagnosed in situ, for which the 5-year relative survival rate is 95%. For tumors diagnosed as a localized, regional, or distant stage, the 5-year survival rate declines to 69%, 35%, and 5%, respectively.

TARGET AUDIENCE

Military, academic, and private practice urologists and other health care professionals involved in the treatment of patients with urothelial carcinoma.

LEARNING OBJECTIVES

1.) Evaluate patient- and tumor-related factors that can inform personalized care plans for patients with urothelial carcinoma
2.) Differentiate the mechanism of action of novel therapies for locally advanced/metastatic urothelial carcinoma
3.) Assess emerging clinical evidence on novel treatment approaches for patients with locally advanced/metastatic urothelial carcinoma, including those ineligible for cisplatin-based chemotherapy